Patients with primary breast carcinoma with axillary lymph node metastases have a high risk of relapse after standard or modified radical mastectomy. Recent updates of the use of adjuvant postoperative chemotherapy in this clinical situation show continuing benefit only in premenopausal and not in postmenopausal women. The anthelmintic, laevotetramisole (levamisole), has been shown to have immunorestorative properties and there are reports of possible benefit using this drug as a clinical 'immunotherapeutic' agent in lung cancer in metastatic breast cancer, and as an adjunct to radiation therapy for locally advanced breast cancer. Since cytotoxic chemotherapy is immunosuppressive and since such immunosuppression theoretically could interfere with host immune responses against a tumor, a clinical trial was designed using a short (6-month) course of chemotherapy coupled with levamisole 'immunorestorative' therapy. A preliminary analysis of the toxicity of this chemoimmunotherapy regimen forms the basis of this report.
|Original language||English (US)|
|Number of pages||3|
|Journal||Cancer Treatment Reports|
|State||Published - Dec 1 1978|
ASJC Scopus subject areas
- Cancer Research